2024-06-27 10:38:07 ET
Summary
- Black Diamond Therapeutics, Inc. is developing a next-generation EGFR inhibitor with promising early data in lung cancer.
- BDTX-1535 targets EGFR mutations, especially resistance drivers, with key data readouts expected in 2024 and early 2025.
- Black Diamond Therapeutics has a strong-enough cash position for now, but the success of their pipeline candidates will be crucial for long-term sustainability.
Topline Summary
Read the full article on Seeking Alpha
For further details see:
Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive